A Study to Evaluate Safety and Efficacy of BEY1107 in Combination with Capecitabine in Patients with Metastatic Colorectal Cancer

An Open-label, Single Center, Phase I/II Clinical Trial to Assess the Maximum Tolerated Dose, Safety and Efficacy of BEY1107 in Combination with Capecitabine in Patients with Metastatic Colorectal Cancer Refractory or Intolerant to Standard of Care

This is a Phase 1/2 study to evaluate the maximum tolerated dose, safety and efficacy of BEY1107 in combination with capecitabine in patients with metastatic colorectal cancer refractory or intolerant to standard of care (SoC).

Study Overview

• Status: Recruiting
• Conditions: Metastatic Colorectal Cancer
• Intervention / Treatment: Drug: BEY1107; Combination product: Capecitabine

Detailed Description

In Phase 1, patients who experienced treatment failure of colorectal cancer with the second-line or beyond standard chemotherapy will be enrolled at each dose level of BEY1107 in combination with Capecitabine. Phase 2 will be conducted after RP2D is determined on the Phase 1 results.

• Study Type: Interventional
• Enrollment (Estimated): 27
• Phase: Phase 2; Phase 1

Contacts and Locations

• Study Contact: Name: BeyondBio Inc.; Phone Number: +82-42-716-0020; Email: clinicaltrials@beyondbio.co.kr

Study Locations

• Korea, Republic of
  • Jongro-go
    • Seoul, Jongro-go, Korea, Republic of, 03080
      • Recruiting
      • Seoul National University Hospial
      • Contact: Beyondbio Inc.; Phone Number: +82-42-716-0020; Email: clicaltrials@beyondbio.co.kr

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 19 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Adult males and females aged over 19 years or older at the time of Informed Consent.
2. Histopathologically or cytologically diagnosed with colorectal cancer.
3. Patients with unresectable metastatic lesion(s).
4. Patients who experienced treatment failure of colorectal cancer with the second-line or beyond standard chemotherapy (including fluoropyrimidine, oxaliplatin and irinotecan).
5. Subjects who have at least one measurable or evaluable lesion as per RECIST v1.1.
6. Subjects with ECOG performance status 0 or 1.
7. Women of childbearing potential who are not surgically sterile must consent to practice acceptable contraception until 6 months after the end of IP administration and also have the evidence of not being fertile.
8. Non-vasectomized men who consent to use an acceptable contraception by one-self and the partner until 3 months after the end of IP administration.
9. Patients who are fully informed of this trial, voluntarily decide to participate in the trial and provide written consent to comply with requirements for the trial.

Exclusion Criteria:

1. Patients who received radiation therapy, chemotherapy or biological agent including hormone therapy recently.
2. Subjects who had a surgery with general anesthesia within 4 weeks of screening.
3. Subjects with symptomatic brain metastasis.
4. Subjects with peripheral neuropathy.
5. Subjects who had findings of affecting absorptin of the IP with gastrointestinal surgery or impossible oral drug administration.
6. Subjects with systemic disease not suitable for anticancer agent administration at the discretion of the investigator.
7. Subjects who had a cardiovascular disease as of screening.
8. Subjects with history of malignancy other than basal cell carcinoma of the skin or cervical carcinoma in situ or papillary thyroid cancer appropriately treated within 5 years.
9. Gastrointestinal bleeding or ulcer.
10. Dihydro-Pyridine Dehydrogenase (DPD) deficiency.
11. Galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption.
12. Hypersensitivity to the ingredient(s) of the investigational product (BEY 1107) or capecitabine, 5-FU (fluorouracil).
13. HIV Positive.
14. Ineligible result of HBV, HCV by the investigator.
15. Acute or severe infection.
16. Subjects who take a Sorivudine or brivudine in combination.
17. Subjects who take a combination of tegafur, gimeracil and oteracil potassium or discontinue within 7 days at the screening.
18. Subjects who take a Rifampin and azole class antifungal drugs in combination.
19. Subjects who has labortory findings of inadequate bone marrow, kidney and liver function.
20. Pregnant women, breastfeeding women, or positive findings on the pregnancy test at screening.
21. Subjects with life expectancy of less than 12 weeks by the investigator.
22. Subjects who had been administered other IP within 4 weeks prior to screening.
23. Subjects determined by the investigator to be ineligible for participation in this trial.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Sequential Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: BEY1107 + Capecitabine; Administer BEY1107 in combination with Capecitabine, 3-weeks as 1 cycle.	Drug: BEY1107; Administer once daily, PO, 3-week continuous dose.; Combination product: Capecitabine; Administer twice daily, PO, 2-week continuous dose, followed by 1-week rest period.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Maximum Tolerated Dose(MTD) assessed by investigator following administration of BEY1107 in combination with Capecitabine	MTD will be assessed based on adverse events(including DLT assessment), vital signs, 12-lead ECG, laboratory tests, etc.	From baseline up to disease progression, approximately 54 weeks
Objective Response Rate(ORR)(Phase 2) assessed by investigator following administration of BEY1107 in combination with Capecitabine	ORR defined as proportion of subjects with a overall response of CR or PR	From baseline up to disease progression, approximately 54 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Pharmacokinetic(PK) of Maximum Serum Concentration (Cmax) of BEY1107 in combination with Capecitabine	Plasma concentrations at each time point and PK parameters Cmax of BEY1107 will be assessed in the PK sampling cohort	From baseline up to 24 hour post-dose
Pharmacokinetic of Time to Reach Maximum Serum Concentration (Tmax) of BEY1107 in combination with Capecitabine	Plasma concentrations at each time point and PK parameters Tmax of BEY1107 will be assessed in the PK sampling cohort	From baseline up to 24 hour post-dose
Pharmacokinetic of Area Under the Serum Concentration-Time Curve Up to Last Quantifiable Time (AUClast) of BEY1107 in combination with Capecitabine	Plasma concentrations at each time point and PK parameters AUClast of BEY1107 will be assessed in the PK sampling cohort	From baseline up to 24 hour post-dose
Progression-free survival(PFS) assessed by investigator following administration of BEY1107 in combination with Capecitabine	PFS is defined as the time from the start of study treatment to the date of the first documentation of objective PD or death due to any cause, whichever is earlier	From baseline up to disease progression, approximately 24 months
Disease control rate(DCR) assessed by investigator following administration of BEY1107 in combination with Capecitabine	DCR is defined as the proportion of participants who achieved a confirmed best overall response (BOR) of complete response (CR), partial response (PR), or stable disease (SD)	From baseline up to approximately 24 months

Collaborators and Investigators

• Sponsor: BeyondBio Inc.

Study record dates

Study Major Dates

• Study Start (Actual): August 31, 2021
• Primary Completion (Estimated): November 30, 2026
• Study Completion (Estimated): December 31, 2026

Study Registration Dates

• First Submitted: September 16, 2021
• First Submitted That Met QC Criteria: October 25, 2021
• First Posted (Actual): October 26, 2021

Study Record Updates

• Last Update Posted (Actual): March 25, 2025
• Last Update Submitted That Met QC Criteria: March 6, 2025
• Last Verified: March 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neoplasms by Site; Neoplasms; Intestinal Diseases; Gastrointestinal Neoplasms; Digestive System Neoplasms; Digestive System Diseases; Gastrointestinal Diseases; Intestinal Neoplasms; Rectal Diseases; Colonic Diseases; Colorectal Neoplasms; Antineoplastic Agents; Molecular Mechanisms of Pharmacological Action; Antimetabolites, Antineoplastic; Antimetabolites; Capecitabine
• Other Study ID Numbers: BEY-2021-01

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No